MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development
Spring House, Pa., May 5, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment (MPAACT), an industry-led research alliance founded in 2018 between Janssen Research & Development, LLC, Genentech (a member of the Roche Group), Novartis, and Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, and recently expanded with additional members Amgen, AbbVie, and Kronos Bio, is advancing efforts to establish measurable residual disease (MRD) as a surrogate endpoint for overall ...
Source: Johnson and Johnson - May 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS
(MedPage Today) -- Eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic cell transplantation (HCT) improved outcomes for patients with TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 25, 2022 Category: Hematology Source Type: news

Ivosidenib + Azacitidine Ups Event-Free Survival in IDH1-Mutated AML
THURSDAY, April 21, 2022 -- Compared with placebo and azacitidine, the combination of ivosidenib and azacitidine prolongs event-free survival for patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are ineligible for induction... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 21, 2022 Category: Pharmaceuticals Source Type: news

Episode 2: Good-Risk Acute Myeloid Leukemia Episode 2: Good-Risk Acute Myeloid Leukemia
Drs Gail Roboz and Gautam Borthakur discuss good-risk acute myeloid leukemia.Medscape (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 14, 2022 Category: Pathology Tags: Hematology-Oncology InDiscussion Source Type: news

Episode 1: Acute Promyelocytic Leukemia: A Subset of Acute Myeloid Leukemia Episode 1: Acute Promyelocytic Leukemia: A Subset of Acute Myeloid Leukemia
Drs Gail Roboz and Farhad Ravandi discuss acute promyelocytic leukemia, a relatively uncommon subset of acute myeloid leukemia.Medscape (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 14, 2022 Category: Pathology Tags: Hematology-Oncology InDiscussion Source Type: news

Africa: First Case of HIV Cure in a Woman After Stem Cell Transplantation Reported At CROI-2022
[WHO] The International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT) P1107 reported the first case of HIV cure in a woman living with HIV submitted to a dual stem cell transplant (i.e., an umbilical cord blood transplant combined with a half-matched bone marrow transplant) for treatment of an acute myelogenous leukemia. The IMPAACT P1107 researchers presented the case details during the oral abstract session held at the 29th Conference on Retroviruses and Opportunistic Infections (CROI 202 (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - April 4, 2022 Category: Infectious Diseases Source Type: news

Survival Inferior in Black Patients With Acute Myeloid Leukemia
Most disparities in acute myeloid leukemia mortality death accounted for by census tract measures (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 23, 2022 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Survival Inferior in Black Patients With Acute Myeloid Leukemia
WEDNESDAY, March 23, 2022 -- For patients with acute myeloid leukemia (AML), non-Hispanic Black individuals have inferior survival to non-Hispanic White individuals, with census tract measures accounting for most of the disparities in survival,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2022 Category: Pharmaceuticals Source Type: news

TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune(R)
Allogeneic unmodified Gamma Delta product can be stored frozen and used as an 'off-the-shelf' cell therapy EDINBURGH, Scotland, March 17, 2022 -- (Healthcare Sales & Marketing Network) -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "... Biopharmaceuticals, Oncology, FDA TC Biopharm, T cell therapy, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 17, 2022 Category: Pharmaceuticals Source Type: news

Mayo Clinic discovery in bone marrow cancer points to potential drug targets  
ROCHESTER, Minn. — New research from Mayo Clinic's Center for Individualized Medicine finds that patients with ASXL1-mutant chronic myelomonocytic leukemia — an uncommon type of cancer of the bone marrow — have distinctive epigenetic changes that can activate harmful genes and cause the cancer to grow faster. The ASXL1 genetic mutation also can transform the disease into the more aggressive acute myeloid leukemia. The study, published in Nature Communications, helps to clarify a potential therapeutic… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 17, 2022 Category: Databases & Libraries Source Type: news

TC Biopharm Announces Appointment of New Board Members
EDINBURGH, Scotland, Feb. 22, 2022 -- (Healthcare Sales & Marketing Network) -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allo... Biopharmaceuticals, Oncology, Personnel TC Biopharm, T cell therapy, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2022 Category: Pharmaceuticals Source Type: news

In study led by UCLA professor, woman with HIV is in remission
UCLA researchers speaking at the Conference on Retroviruses and Opportunistic Infections have presented the first case  of a U.S. woman living with HIV-1 that is in remission.The woman, who was diagnosed with acute HIV in 2013 and acute myeloid leukemia in 2017, received umbilical cord blood cells as a treatment for her cancer. The leukemia has been in remission for four-and-a-half years, and there has been no rebound of HIV in the 14 months since antiretroviral therapy ended.The woman was part of a multicenter study that  was funded by the National Institutes of Health and led by Dr. Yvonne Bryson, chief of pediatric i...
Source: UCLA Newsroom: Health Sciences - February 17, 2022 Category: Universities & Medical Training Source Type: news

Blast Counts Not Enough to Distinguish MDS From AML, Experts Say Blast Counts Not Enough to Distinguish MDS From AML, Experts Say
Oncologists argue that in differentiating myelodysplastic syndrome from acute myeloid leukemia, more than just bone marrow blast cutoff should be considered.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news

Polygenic Score Helps Guide Choice of Chemo for Pediatric AML
TUESDAY, Feb. 1, 2022 -- A polygenic score derived from pharmacogenomic evaluation of cytarabine (ara-C) pathway can help personalize treatment for pediatric patients with acute myeloid leukemia (AML), according to a study published online Jan. 18... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2022 Category: Pharmaceuticals Source Type: news